WVE-006
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RestorAATion-1 NCT06186492 · Alpha-1 Antitrypsin Deficiency RestorAATion-1 was a randomized, double-blind, placebo-controlled first-in-human Phase 1 study of WVE-006 in healthy volunteers. Its primary outcome was adverse events, with no efficacy hypothesis, so there is no result to call met or missed. Adverse events occurred at similar rates with WVE-006 and placebo. Source: CT.gov posted results. Registry: NCT06186492 | 1 | The Proportion of Participants With Adverse Events (Adverse events are collected from the date of consent until up to 85 days after the dose in Period 1 and up to 113 days after the first dose in Period 2.) 2025-02-13 | First-in-human study in healthy volunteers; the registered primary was the proportion of participants with adverse events, with no formal test: Period 1 single doses 30 to 600 mg 3/6 to 5/6 vs pooled placebo 8/10; Period 2 600 mg every 2 weeks 2/6 vs placebo 1/2 (CT.gov posted results). | not yet graded | link ↗ |
View 1 more trial
NCT06405633 NCT06405633 · Alpha-1 Antitrypsin Deficiency Registry: NCT06405633 | 1/2 | The proportion of participants with adverse events (Up to 36 Weeks) 2027-09 | In progress: results expected 1 Sept 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| WVE-006: this drug | Phase 1/2 | RNA / oligonucleotide | SERPINA1 Z-allele mRNA (ADAR-mediated editing) | not yet graded | No reviewed efficacy summary in this indication | |
| Fazirsiran | Phase 3 | RNA / oligonucleotide | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| BEAM-302 | Phase 1/2 | Gene therapy / editing | SERPINA1 PiZ mutation (E342K) | not yet graded | No reviewed efficacy summary in this indication | |
| TSRA-196 | Phase 1/2 | Gene therapy / editing | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| KB408 | Phase 1 | Gene therapy / editing | SERPINA1 (alpha-1 antitrypsin; gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Efdoralprin Alfa | —(overall) | Protein / enzyme therapeutic | Alpha-1 antitrypsin (AAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow WVE-006 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent